PURPOSE: As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 human ovarian carcinoma cells. METHODS: Time-course and concentration-effect experiments were each carried out with cisplatin or oxaliplatin in two separate experiments and cells subjected to gene expression profiling using Affymetrix array technology. Time-course data were modeled using exponential increase and decrease models. Concentration-effect data were modeled using a four parameter Hill model. RESULTS: Gene expression profiling of human ovarian carcinoma A2780 cells after exposure to either cisplatin or oxaliplatin indicates that the expression of several genes involved in polyamine pathway is affected by the platinum drugs. Mathematical/Statistical modeling of the data from time-course and concentration-effect experiments of gene expression from nine polyamine pathway genes represented on the HGU95Av2 chip, indicates that three biosynthetic pathway genes (SAMDC, ODC1 and SRM) are down-regulated and one catabolic pathway gene (SSAT) is up-regulated. Expression changes were similar for different probesets for a given gene on the array. Studies on the induction of SSAT by platinum drugs suggested by the Affymetrix data have been previously validated from this laboratory (Hector et al. in Mol Cancer Ther 3:813-822, 2004). Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR. CONCLUSION: The data indicate a concerted effect of platinum drugs on the polyamine metabolic pathway with down-regulation in the expression of several enzyme genes involved in biosynthesis and many-fold up-regulation in expression of SSAT, an acetylating enzyme gene that is critically involved in polyamine catabolism and export.
PURPOSE: As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 humanovarian carcinoma cells. METHODS: Time-course and concentration-effect experiments were each carried out with cisplatin or oxaliplatin in two separate experiments and cells subjected to gene expression profiling using Affymetrix array technology. Time-course data were modeled using exponential increase and decrease models. Concentration-effect data were modeled using a four parameter Hill model. RESULTS: Gene expression profiling of humanovarian carcinoma A2780 cells after exposure to either cisplatin or oxaliplatin indicates that the expression of several genes involved in polyamine pathway is affected by the platinum drugs. Mathematical/Statistical modeling of the data from time-course and concentration-effect experiments of gene expression from nine polyamine pathway genes represented on the HGU95Av2 chip, indicates that three biosynthetic pathway genes (SAMDC, ODC1 and SRM) are down-regulated and one catabolic pathway gene (SSAT) is up-regulated. Expression changes were similar for different probesets for a given gene on the array. Studies on the induction of SSAT by platinum drugs suggested by the Affymetrix data have been previously validated from this laboratory (Hector et al. in Mol Cancer Ther 3:813-822, 2004). Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR. CONCLUSION: The data indicate a concerted effect of platinum drugs on the polyamine metabolic pathway with down-regulation in the expression of several enzyme genes involved in biosynthesis and many-fold up-regulation in expression of SSAT, an acetylating enzyme gene that is critically involved in polyamine catabolism and export.
Authors: Xiaofei Chang; Constance L Monitto; Semra Demokan; Myoung Sook Kim; Steven S Chang; Xiaoli Zhong; Joseph A Califano; David Sidransky Journal: Cancer Res Date: 2010-03-09 Impact factor: 12.701
Authors: Ramakumar Tummala; Paula Diegelman; Sonia M Fiuza; Luis A E Batista de Carvalho; Maria Paula M Marques; Debora L Kramer; Kimberly Clark; Slavoljub Vujcic; Carl W Porter; Lakshmi Pendyala Journal: Oncol Rep Date: 2010-07 Impact factor: 3.906
Authors: Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber Journal: Cancer Res Date: 2008-12-01 Impact factor: 12.701
Authors: Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson Journal: Cancer Chemother Pharmacol Date: 2009-08-30 Impact factor: 3.333
Authors: Rui-Ru Ji; Heshani de Silva; Yisheng Jin; Robert E Bruccoleri; Jian Cao; Aiqing He; Wenjun Huang; Paul S Kayne; Isaac M Neuhaus; Karl-Heinz Ott; Becky Penhallow; Mark I Cockett; Michael G Neubauer; Nathan O Siemers; Petra Ross-Macdonald Journal: PLoS Comput Biol Date: 2009-09-18 Impact factor: 4.475
Authors: Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero Journal: Cancer Chemother Pharmacol Date: 2020-11-19 Impact factor: 3.333